Mepolizumab alters gene regulatory networks of nasal airway type-2 and epithelial inflammation in urban children with asthma

Abstract Mepolizumab (anti-IL5 therapy) reduces asthma exacerbations in urban children with exacerbation-prone eosinophilic asthma. We previously utilized nasal transcriptomics to identify inflammatory pathways (gene co-expression modules) associated with asthma exacerbations despite this therapy. I...

Ful tanımlama

Kaydedildi:

Detaylı Bibliyografya
Asıl Yazarlar:	Courtney L. Gaberino, R. Max Segnitz, Kimberly A. Dill-McFarland, Leonard B. Bacharier, Agustin Calatroni, Michelle A. Gill, Jeffrey Stokes, Andrew H. Liu, Robyn T. Cohen, Rajesh Kumar, Abigail Lang, Gurjit K. Khurana Hershey, Michael G. Sherenian, Edward M. Zoratti, Stephen J. Teach, Meyer Kattan, Patrice M. Becker, Alkis Togias, William W. Busse, Daniel J. Jackson, Matthew C. Altman
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	Nature Portfolio 2025-09-01
Seri Bilgileri:	Nature Communications
Online Erişim:	https://doi.org/10.1038/s41467-025-63629-2
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Mepolizumab alters gene regulatory networks of nasal airway type-2 and epithelial inflammation in urban children with asthma

Benzer Materyaller